{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:22:37Z","timestamp":1787239357120,"version":"build-2736575974"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"DOI":"10.1186\/s12877-025-06745-4","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T01:03:50Z","timestamp":1764983030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment patterns of symptomatic treatments for Alzheimer\u2019s disease and related dementias"],"prefix":"10.1186","volume":"26","author":[{"given":"Huiwen","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Gaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kibum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Y.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica G.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sengwee","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"6745_CR1","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","volume":"20","author":"2024 Alzheimer\u2019s disease facts and figures","year":"2024","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2024;20:3708\u2013821. https:\/\/doi.org\/10.1002\/alz.13809.","journal-title":"Alzheimers Dement"},{"key":"6745_CR2","unstructured":"2024 NIH Alzheimer\u2019s and Related Dementias Research Progress Report: Advances and Achievements. https:\/\/www.nia.nih.gov\/sites\/default\/files\/2024-08\/2024-alzheimers-progress-report.pdf. Accessed 08 Jan 2024."},{"key":"6745_CR3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-180903","volume":"67","author":"GT Grossberg","year":"2018","unstructured":"Grossberg GT, Tong G, Burke AD, Tariot PN. Present algorithms and future treatments for alzheimer\u2019s disease. J Alzheimers Dis. 2018;67:1157\u201371. https:\/\/doi.org\/10.3233\/JAD-180903.","journal-title":"J Alzheimers Dis"},{"key":"6745_CR4","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamaneurol.2022.3543","volume":"79","author":"JJ Manly","year":"2022","unstructured":"Manly JJ, Jones RN, Langa KM, Ryan LH, Levine DA, McCammon R, et al. Estimating the prevalence of dementia and mild cognitive impairment in the US: the 2016 health and retirement study harmonized cognitive assessment protocol project. JAMA Neurol. 2022;79:1242\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3543.","journal-title":"JAMA Neurol"},{"key":"6745_CR5","unstructured":"FDA Converts Novel Alzheimer\u2019s Disease Treatment to Traditional Approval. FDA. 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Accessed 16 Aug 2023."},{"key":"6745_CR6","unstructured":"FDA Grants Accelerated Approval for Alzheimer\u2019s Drug. FDA. 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug. Accessed 16 Aug 2023."},{"key":"6745_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/JAD-200133","volume":"76","author":"D Barthold","year":"2020","unstructured":"Barthold D, Joyce G, Ferido P, Drabo EF, Marcum ZA, Gray SL, et al. Pharmaceutical treatment for Alzheimer\u2019s disease and related dementias: utilization and disparities. J Alzheimers Dis. 2020;76:579\u201389. https:\/\/doi.org\/10.3233\/JAD-200133.","journal-title":"J Alzheimers Dis"},{"key":"6745_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1212\/01.wnl.0000167545.38161.48","volume":"65","author":"KM Mehta","year":"2005","unstructured":"Mehta KM, Yin M, Resendez C, Yaffe K. Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease. Neurology. 2005;65:159\u201362. https:\/\/doi.org\/10.1212\/01.wnl.0000167545.38161.48.","journal-title":"Neurology"},{"key":"6745_CR9","doi-asserted-by":"publisher","first-page":"S328","DOI":"10.1093\/geronb\/63.5.S328","volume":"63","author":"IH Zuckerman","year":"2008","unstructured":"Zuckerman IH, Ryder PT, Simoni-Wastila L, Shaffer T, Sato M, Zhao L, et al. Racial and ethnic disparities in the treatment of dementia among medicare beneficiaries. J Gerontol B Psychol Sci Soc Sci. 2008;63:S328\u201333.","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"6745_CR10","doi-asserted-by":"publisher","first-page":"CD003154","DOI":"10.1002\/14651858.CD003154.pub6","volume":"2019","author":"R McShane","year":"2019","unstructured":"McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;2019:CD003154. https:\/\/doi.org\/10.1002\/14651858.CD003154.pub6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"6745_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593","volume":"2016","author":"JS Birks","year":"2006","unstructured":"Birks JS. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;CD005593. https:\/\/doi.org\/10.1002\/14651858.CD005593.","journal-title":"Cochrane Database Syst Rev"},{"key":"6745_CR12","unstructured":"Dementia. Assessment, management and support for people living with dementia and their carers. 2018. https:\/\/www.nice.org.uk\/guidance\/ng97. Accessed 8 Jan 2024."},{"key":"6745_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.7326\/0003-4819-148-5-200803040-00008","volume":"148","author":"A Qaseem","year":"2008","unstructured":"Qaseem A, Snow V, Cross JT, Forciea MA, Hopkins R, Shekelle P, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American college of physicians and the American academy of family physicians. Ann Intern Med. 2008;148:370\u20138. https:\/\/doi.org\/10.7326\/0003-4819-148-5-200803040-00008.","journal-title":"Ann Intern Med"},{"key":"6745_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1176\/appi.focus.15106","volume":"15","author":"PV Rabins","year":"2017","unstructured":"Rabins PV, Rovner BW, Rummans T, Schneider LS, Tariot PN, Guideline Watch. (October 2014): practice guideline for the treatment of patients with alzheimer\u2019s disease and other dementias. FOCUS. 2017;15:110\u201328. https:\/\/doi.org\/10.1176\/appi.focus.15106.","journal-title":"FOCUS"},{"key":"6745_CR15","unstructured":"Guideline Adaptation Committee. Clinical Practice Guidelines and Principles of Care for People with Dementia. 2016. https:\/\/cdpc.sydney.edu.au\/wp-content\/uploads\/2019\/06\/CDPC-Dementia-Guidelines_WEB.pdf."},{"key":"6745_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/15622975.2010.538083","volume":"12","author":"R Ihl","year":"2011","unstructured":"Ihl R, Fr\u00f6lich L, Winblad B, Schneider L, Burns A, M\u00f6ller H-J. World federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer\u2019s disease and other dementias. World J Biol Psychiatry. 2011;12:2\u201332. https:\/\/doi.org\/10.3109\/15622975.2010.538083.","journal-title":"World J Biol Psychiatry"},{"key":"6745_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40266-015-0266-9","volume":"32","author":"JS Buckley","year":"2015","unstructured":"Buckley JS, Salpeter SR. A risk-benefit assessment of dementia medications: systematic review of the evidence. Drugs Aging. 2015;32:453\u201367. https:\/\/doi.org\/10.1007\/s40266-015-0266-9.","journal-title":"Drugs Aging"},{"key":"6745_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1192\/bjp.2020.136","volume":"218","author":"N Vaci","year":"2021","unstructured":"Vaci N, Koychev I, Kim C-H, Kormilitzin A, Liu Q, Lucas C, et al. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study. Br J Psychiatry. 2021;218:261\u20137. https:\/\/doi.org\/10.1192\/bjp.2020.136.","journal-title":"Br J Psychiatry"},{"key":"6745_CR19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/gps.2384","volume":"25","author":"RW Jones","year":"2010","unstructured":"Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry. 2010;25:547\u201353. https:\/\/doi.org\/10.1002\/gps.2384.","journal-title":"Int J Geriatr Psychiatry"},{"key":"6745_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1517\/14740338.3.5.425","volume":"3","author":"S Thompson","year":"2004","unstructured":"Thompson S, Lanct\u00f4t KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer\u2019s disease. Expert Opin Drug Saf. 2004;3:425\u201340. https:\/\/doi.org\/10.1517\/14740338.3.5.425.","journal-title":"Expert Opin Drug Saf"},{"key":"6745_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40266-015-0273-x","volume":"32","author":"WJ Deardorff","year":"2015","unstructured":"Deardorff WJ, Feen E, Grossberg GT. The use of cholinesterase inhibitors across all stages of Alzheimer\u2019s disease. Drugs Aging. 2015;32:537\u201347. https:\/\/doi.org\/10.1007\/s40266-015-0273-x.","journal-title":"Drugs Aging"},{"key":"6745_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/11530300-000000000-00000","volume":"24","author":"A Pariente","year":"2010","unstructured":"Pariente A, Sanctussy DJ-R, Miremont-Salam\u00e9 G, Moore N, Haramburu F, Fourrier-R\u00e9glat A, et al. Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. CNS Drugs. 2010;24:55\u201363. https:\/\/doi.org\/10.2165\/11530300-000000000-00000.","journal-title":"CNS Drugs"},{"key":"6745_CR23","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2147\/CIA.S87466","volume":"10","author":"G Pasqualetti","year":"2015","unstructured":"Pasqualetti G, Tognini S, Calsolaro V, Polini A, Monzani F. Potential drug-drug interactions in alzheimer patients with behavioral symptoms. Clin Interv Aging. 2015;10:1457\u201366. https:\/\/doi.org\/10.2147\/CIA.S87466.","journal-title":"Clin Interv Aging"},{"key":"6745_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/14656566.2011.558006","volume":"12","author":"N Herrmann","year":"2011","unstructured":"Herrmann N, Li A, Lanct\u00f4t K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother. 2011;12:787\u2013800. https:\/\/doi.org\/10.1517\/14656566.2011.558006.","journal-title":"Expert Opin Pharmacother"},{"key":"6745_CR25","unstructured":"Evidence-based. Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine: Recommendations. 2018. https:\/\/cdpc.sydney.edu.au\/wp-content\/uploads\/2019\/06\/deprescribing-guideline.pdf."},{"key":"6745_CR26","doi-asserted-by":"publisher","unstructured":"Ott BR, Hollins C, Tjia J, Baek J, Chen Q, Lapane KL, et al. Antidementia medication use in nursing home residents. J Geriatr Psychiatry Neurol. 2023(3). https:\/\/doi.org\/10.1177\/08919887231202948.","DOI":"10.1177\/08919887231202948"},{"key":"6745_CR27","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2008.14.5.451","author":"L Mucha","year":"2008","unstructured":"Mucha L, Wang SS, Cuffel B, McRae T, Mark TL, del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer\u2019s disease. J Manag Care Pharm. 2008. https:\/\/doi.org\/10.18553\/jmcp.2008.14.5.451.","journal-title":"J Manag Care Pharm"},{"key":"6745_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03447-5","volume":"23","author":"JR DiBello","year":"2023","unstructured":"DiBello JR, Lu Y, Swartz J, Bortnichak EA, Liaw K-L, Zhong W, et al. Patterns of use of symptomatic treatments for Alzheimer\u2019s disease dementia (AD). BMC Neurol. 2023;23:400. https:\/\/doi.org\/10.1186\/s12883-023-03447-5.","journal-title":"BMC Neurol"},{"key":"6745_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40120-017-0067-7","volume":"6","author":"N Bent-Ennakhil","year":"2017","unstructured":"Bent-Ennakhil N, Coste F, Xie L, Aigbogun MS, Wang Y, Kariburyo F, et al. A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed alzheimer\u2019s disease patients. Neurol Ther. 2017;6:131\u201344. https:\/\/doi.org\/10.1007\/s40120-017-0067-7.","journal-title":"Neurol Ther"},{"issue":"4","key":"6745_CR30","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/alz.12753","volume":"9","author":"N Olchanski","year":"2022","unstructured":"Olchanski N, Daly AT, Zhu Y, Breslau R, Cohen JT, Neumann PJ, et al. Alzheimer\u2019s disease medication use and adherence patterns by race and ethnicity. Alzheimers Dement. 2022. https:\/\/doi.org\/10.1002\/alz.12753.","journal-title":"Alzheimers Dement"},{"issue":"S10","key":"6745_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/alz.054849","volume":"17","author":"P Lin","year":"2021","unstructured":"Lin P, Daly A, Olchanski N, Zhu Y, Cohen JT, Neumann PJ, et al. Alzheimer\u2019s disease medication utilization patterns: disparities in treatment initiation, non-adherence, and discontinuation. Alzheimers Dement. 2021;17(S10):e054849. https:\/\/doi.org\/10.1002\/alz.054849.","journal-title":"Alzheimers Dement"},{"key":"6745_CR32","unstructured":"MarketScan Research Databases - Overview. 2022. https:\/\/www.ibm.com\/products\/marketscan-research-databases. Accessed 20 July 2022."},{"key":"6745_CR33","unstructured":"IBM MarketScan. Research Databases for life sciences researchers. 2018. https:\/\/www.conferenceharvester.com\/uploads\/harvester\/exhibitors\/2854\/DLEHLADK-PDF-518347-465802-1-PDF.pdf Accessed 8 Jan 2024."},{"key":"6745_CR34","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6620a1","author":"CA Taylor","year":"2017","unstructured":"Taylor CA, Greenlund SF, McGuire LC, Lu H, Croft JB. Deaths from alzheimer\u2019s disease \u2014 United States, 1999\u20132014. MMWR Morb Mortal Wkly Rep. 2017. https:\/\/doi.org\/10.15585\/mmwr.mm6620a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6745_CR35","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/gerona\/glab373","volume":"77","author":"EP McCarthy","year":"2021","unstructured":"McCarthy EP, Chang C-H, Tilton N, Kabeto MU, Langa KM, Bynum JPW. Validation of claims algorithms to identify Alzheimer\u2019s disease and related dementias. J Gerontol A Biol Sci Med Sci. 2021;77:1261\u201371. https:\/\/doi.org\/10.1093\/gerona\/glab373.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"6745_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020250","volume":"8","author":"L McWilliams","year":"2018","unstructured":"McWilliams L, Farrell C, Keady J, Swarbrick C, Burgess L, Grande G, et al. Cancer-related information needs and treatment decision-making experiences of people with dementia in England: a multiple perspective qualitative study. BMJ Open. 2018;8:e020250. https:\/\/doi.org\/10.1136\/bmjopen-2017-020250.","journal-title":"BMJ Open"},{"key":"6745_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0407-4","volume":"17","author":"J Czwikla","year":"2017","unstructured":"Czwikla J, Jobski K, Schink T. The impact of the lookback period and definition of confirmatory events on the identification of incident cancer cases in administrative data. BMC Med Res Methodol. 2017;17:122. https:\/\/doi.org\/10.1186\/s12874-017-0407-4.","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"6745_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/pds.4435","volume":"27","author":"MM Conover","year":"2018","unstructured":"Conover MM, St\u00fcrmer T, Poole C, Glynn RJ, Simpson RJ, Pate V, et al. Classifying medical histories in US medicare beneficiaries using fixed vs all-available look-back approaches. Pharmacoepidemiol Drug Saf. 2018;27(7):771\u201380. https:\/\/doi.org\/10.1002\/pds.4435.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6745_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-5016-y","volume":"20","author":"M Kim","year":"2020","unstructured":"Kim M, Chae K-H, Chung Y-J, Hwang H, Lee M, Kim H-K, et al. The effect of the look-back period for estimating incidence using administrative data. BMC Health Serv Res. 2020;20:166. https:\/\/doi.org\/10.1186\/s12913-020-5016-y.","journal-title":"BMC Health Serv Res"},{"key":"6745_CR40","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1742-1241.2009.02052.x","volume":"63","author":"A Kurz","year":"2009","unstructured":"Kurz A, Farlow M, Lef\u00e8vre G. Pharmacokinetics of a novel transdermal Rivastigmine patch for the treatment of Alzheimer\u2019s disease: a review. Int J Clin Pract. 2009;63:799\u2013805. https:\/\/doi.org\/10.1111\/j.1742-1241.2009.02052.x.","journal-title":"Int J Clin Pract"},{"key":"6745_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/sj.clpt.6100242","volume":"83","author":"G Lef\u00e8vre","year":"2008","unstructured":"Lef\u00e8vre G, Sedek G, Jhee SS, Leibowitz MT, Huang H-L, Enz A, et al. Pharmacokinetics and pharmacodynamics of the novel daily Rivastigmine transdermal patch compared with twice-daily capsules in alzheimer\u2019s disease patients. Clin Pharmacol Ther. 2008;83:106\u201314. https:\/\/doi.org\/10.1038\/sj.clpt.6100242.","journal-title":"Clin Pharmacol Ther"},{"key":"6745_CR42","unstructured":"Drugs@FDA. FDA-Approved Drugs. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drugsfda-data-files. Accessed date 08 Jan 2024."},{"key":"6745_CR43","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1002\/pds.2019","volume":"19","author":"K Bloomfield","year":"2010","unstructured":"Bloomfield K, John N, McGrogan A, Jones R, De Vries C. Co-Prescribing of medications with anticholinergicproperties to those using cholinesterase inhibitors fordementia. Pharmacoepidemiol Drug Saf. 2010;19:S48. https:\/\/doi.org\/10.1002\/pds.2019.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"6745_CR44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2165\/11318010-000000000-00000","volume":"24","author":"V Gardette","year":"2010","unstructured":"Gardette V, Andrieu S, Lapeyre-Mestre M, Coley N, Cantet C, Ousset P-J, et al. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer\u2019s disease: a 2-year prospective, multicentre, cohort study. CNS Drugs. 2010;24:431\u201342. https:\/\/doi.org\/10.2165\/11318010-000000000-00000.","journal-title":"CNS Drugs"},{"key":"6745_CR45","unstructured":"Two types of drugs you may want to avoid for the sake of your brain. Harvard Health. 2015. https:\/\/www.health.harvard.edu\/mind-and-mood\/two-types-of-drugs-you-may-want-to-avoid-for-the-sake-of-your-brain. Accessed 24 July 2023."},{"key":"6745_CR46","unstructured":"Census Regions and Divisions of the United States. U.S. Department of Commerce Economics and Statistics Administration U.S. Census Bureau; https:\/\/www2.census.gov\/geo\/pdfs\/maps-data\/maps\/reference\/us_regdiv.pdf. Accessed date 08 Jan 2024."},{"key":"6745_CR47","unstructured":"ZIP Code\u2122 Lookup | USPS. 2024. https:\/\/tools.usps.com\/zip-code-lookup.htm?citybyzipcode. Accessed 8 Jan 2024."},{"issue":"7","key":"6745_CR48","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","volume":"64","author":"JJ Gagne","year":"2011","unstructured":"Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64:749\u201359. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.10.004.","journal-title":"J Clin Epidemiol"},{"key":"6745_CR49","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MLR.0000000000000824","volume":"55","author":"JW Sun","year":"2017","unstructured":"Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, et al. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55:1046\u201351. https:\/\/doi.org\/10.1097\/MLR.0000000000000824.","journal-title":"Med Care"},{"issue":"11","key":"6745_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glad166","volume":"78","author":"CM Park","year":"2023","unstructured":"Park CM, Sison SDM, McCarthy EP, Shi S, Gouskova N, Lin KJ, et al. Claims-based frailty index as a measure of dementia severity in medicare claims data. J Gerontol A Biol Sci Med Sci. 2023;glad166. https:\/\/doi.org\/10.1093\/gerona\/glad166.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"6745_CR51","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","volume":"73","author":"DH Kim","year":"2018","unstructured":"Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in medicare data: development and validation of a claims-based frailty index. J Gerontol A Biol Sci Med Sci. 2018;73:980\u20137. https:\/\/doi.org\/10.1093\/gerona\/glx229.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"6745_CR52","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jalz.2012.02.005","volume":"9","author":"X Cai","year":"2013","unstructured":"Cai X, Campbell N, Khan B, Callahan C, Boustani M. Chronic anticholinergic use and the aging brain. Alzheimers Dement J Alzheimers Assoc. 2013;9:377\u201385. https:\/\/doi.org\/10.1016\/j.jalz.2012.02.005.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"6745_CR53","unstructured":"John R, Horn P, Philip D, Hansten P. Drug Interactions with CYP3A4: An Update. 2015;81. https:\/\/www.pharmacytimes.com\/view\/drug-interactions-with-cyp3a4-an-update"},{"key":"6745_CR54","unstructured":"John R, Horn P, Philip D, Hansten P. Get to Know an Enzyme: CYP2D6. 2008;0.0 https:\/\/www.pharmacytimes.com\/view\/2008-07-8624"},{"issue":"25","key":"6745_CR55","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697.","journal-title":"Stat Med"},{"key":"6745_CR56","first-page":"141","volume":"5","author":"Odd O Aalen","year":"1978","unstructured":"Aalen OO, Johansen S. An empirical transition matrix for Non-Homogeneous Markov chains based on censored observations. Scand J Stat. 1978;5:141\u201350. https:\/\/www.jstor.org\/stable\/4615704","journal-title":"Scand J Stat"},{"key":"6745_CR57","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017719.","journal-title":"Circulation"},{"key":"6745_CR58","unstructured":"Joseph C. Gardiner. Competing Risks Analyses: Overview of Regression Models. 2016. https:\/\/support.sas.com\/resources\/papers\/proceedings16\/8620-2016.pdf"},{"key":"6745_CR59","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"J Robert","year":"1988","unstructured":"Robert J, Gray. A class of K-Sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16:1141\u201354. https:\/\/doi.org\/10.1214\/aos\/1176350951.","journal-title":"Ann Statist"},{"issue":"1412","key":"6745_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7447.1073","volume":"328","author":"JM Bland","year":"2004","unstructured":"Bland JM, Altman DG. The logrank test. BMJ. 2004;328:1073. https:\/\/doi.org\/10.1136\/bmj.328.7447.1073.","journal-title":"BMJ"},{"key":"6745_CR61","unstructured":"Transition to ICD-10. https:\/\/www.dol.gov\/agencies\/owcp\/FECA\/ICD10transition. Accessed 08 Jan 2024."},{"key":"6745_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1017\/S1041610292001157","volume":"4","author":"SG Sclan","year":"1992","unstructured":"Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer\u2019s disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992;4:55\u201369. https:\/\/doi.org\/10.1017\/S1041610292001157.","journal-title":"Int Psychogeriatr"},{"issue":"446","key":"6745_CR63","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2307\/2670170","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509. https:\/\/doi.org\/10.2307\/2670170.","journal-title":"J Am Stat Assoc"},{"key":"6745_CR64","unstructured":"Sara Conroy, Eleanor J, Murray. Apr. Let the question determine the methods: descriptive epidemiology done right - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/32814836\/. Accessed 08 Jan 2025."},{"key":"6745_CR65","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1111\/ene.15053","volume":"28","author":"C Ju","year":"2021","unstructured":"Ju C, Wong ICK, Lau WCY, Man KKC, Brauer R, Ma T-T, et al. Global trends in symptomatic medication use against dementia in 66 countries\/regions from 2008 to 2018. Eur J Neurol. 2021;28:3979\u201389. https:\/\/doi.org\/10.1111\/ene.15053.","journal-title":"Eur J Neurol"},{"key":"6745_CR66","unstructured":"U.S. Pharmacist. FDA Approves Generic Aricept. 2010. https:\/\/www.uspharmacist.com\/article\/fda-approves-generic-aricept. Accessed 26 Dec 2023."},{"key":"6745_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5784","volume":"33","author":"JD Niznik","year":"2024","unstructured":"Niznik JD, Shmuel S, Pate V, Thorpe CT, Hanson LC, Rice C, et al. Validating claims-based definitions for deprescribing: bridging the gap between clinical and administrative data. Pharmacoepidemiol Drug Saf. 2024;33:e5784. https:\/\/doi.org\/10.1002\/pds.5784.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6745_CR68","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/jgs.15985","volume":"67","author":"JD Niznik","year":"2019","unstructured":"Niznik JD, Zhao X, He M, Aspinall SL, Hanlon JT, Nace D, et al. Factors associated with deprescribing acetylcholinesterase inhibitors in older nursing home residents with severe dementia. J Am Geriatr Soc. 2019;67:1871\u20139. https:\/\/doi.org\/10.1111\/jgs.15985.","journal-title":"J Am Geriatr Soc"},{"key":"6745_CR69","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","volume":"41","author":"C-C Tan","year":"2014","unstructured":"Tan C-C, Yu J-T, Wang H-F, Tan M-S, Meng X-F, Wang C, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41:615\u201331. https:\/\/doi.org\/10.3233\/JAD-132690.","journal-title":"J Alzheimers Dis"},{"key":"6745_CR70","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5694\/mja2.50015","volume":"210","author":"E Reeve","year":"2019","unstructured":"Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019;210:174\u20139. https:\/\/doi.org\/10.5694\/mja2.50015.","journal-title":"Med J Aust"},{"key":"6745_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02412-1","volume":"24","author":"L Zhang","year":"2024","unstructured":"Zhang L, Bujkiewicz S, Jackson D. Three new methodologies for calculating the effective sample size when performing population adjustment. BMC Med Res Methodol. 2024;24:287. https:\/\/doi.org\/10.1186\/s12874-024-02412-1.","journal-title":"BMC Med Res Methodol"},{"key":"6745_CR72","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/sj.bjc.6602102","volume":"91","author":"JM Satagopan","year":"2004","unstructured":"Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer. 2004;91:1229\u201335. https:\/\/doi.org\/10.1038\/sj.bjc.6602102.","journal-title":"Br J Cancer"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06745-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-025-06745-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06745-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:20:53Z","timestamp":1768342853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12877-025-06745-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6745"],"URL":"https:\/\/doi.org\/10.1186\/s12877-025-06745-4","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data within the MarketScan database are Health Insurance Portability and Accountability Act-compliant and the study was approved by the University of Illinois Chicago and the Harvard Pilgrim Health Care institutional review boards. Consent was not necessary for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HD is a full-time employee at AbbVie Inc., for unrelated work; CG receives academic salary support from AbbVie Inc. for administering an academic fellowship, unrelated to this work; KK receives salary support from Takeda Pharmaceuticals for a fellowship program and received salary support from the Institute of Clinical and Economic Review for a research program, both of which are unrelated to this work; ST serves as a methods consultant for Pfizer, Inc. for unrelated work. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}